BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 23081885)

  • 21. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
    Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
    Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.
    Huang H; Kang R; Wang J; Luo G; Yang W; Zhao Z
    Autophagy; 2013 Feb; 9(2):175-95. PubMed ID: 23169238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.
    Carroll B; Maetzel D; Maddocks OD; Otten G; Ratcliff M; Smith GR; Dunlop EA; Passos JF; Davies OR; Jaenisch R; Tee AR; Sarkar S; Korolchuk VI
    Elife; 2016 Jan; 5():. PubMed ID: 26742086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
    Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
    Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
    Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.
    Syed F; Sanganee HJ; Singh S; Bahl A; Bayat A
    J Invest Dermatol; 2013 May; 133(5):1340-50. PubMed ID: 23303455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
    Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
    Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
    Huang J; Dibble CC; Matsuzaki M; Manning BD
    Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
    Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
    PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation.
    Prabowo AS; Anink JJ; Lammens M; Nellist M; van den Ouweland AM; Adle-Biassette H; Sarnat HB; Flores-Sarnat L; Crino PB; Aronica E
    Brain Pathol; 2013 Jan; 23(1):45-59. PubMed ID: 22805177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.
    Yasuda S; Sugiura H; Katsurabayashi S; Shimada T; Tanaka H; Takasaki K; Iwasaki K; Kobayashi T; Hino O; Yamagata K
    Sci Rep; 2014 Jun; 4():5155. PubMed ID: 24889507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
    Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
    J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
    Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
    Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway.
    Tan SH; Shui G; Zhou J; Shi Y; Huang J; Xia D; Wenk MR; Shen HM
    Autophagy; 2014 Feb; 10(2):226-42. PubMed ID: 24296537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
    Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
    PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
    Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
    Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.